VNDRIQ — Vendor Comparison
Craniocatch vs Allisone
Side-by-side comparison of BAA status, PHI exposure, AI training risk, HIPAA suitability, and VNDRIQ governance scores.
Craniocatch
Dental Imaging AI
Verification pending
Allisone
Dental Imaging AI
Verification pending
VNDRIQ Scores
41
Overall
41
Overall
Approval Tier
BAA Status
PHI Exposure Risk
AI Training Risk
HIPAA Risk Level
Review Frequency
Quarterly
Quarterly
Recommended Use
Educational and research purposes; clinical use is currently restricted in the United States due to the absence of FDA marketing authorization.
AI-assisted interpretation of 2D dental radiographs and visual patient education to improve treatment plan acceptance.
Restrictions
Lacks verified FDA 510(k) clearance for clinical deployment within the United States as of recent regulatory reviews.
Intended for use by qualified dental surgeons only; AI findings must be verified by a practitioner. US-based practices must verify HIPAA compliance and BAA availability before use.
Executive Summary
Craniocatch
Dental Imaging AI
Craniocatch is classified as Restricted / Review Required with a BAA status of No publicly available Business Associate Agreement (BAA) was identified; the company is headquartered in Turkey and lacks verified FDA clearance for US clinical use.. PHI exposure is rated High and AI training risk is Medium. Educational and research purposes; clinical use is currently restricted in the United States due to the absence of FDA marketing authorization.
36
Privacy
37
Governance
35
Healthcare
55
AI Risk
Allisone
Dental Imaging AI
Allisone is classified as Restricted / Review Required with a BAA status of No public evidence of a Business Associate Agreement (BAA) was found in the search results; the company primarily highlights its CE Class IIa medical device certification for the European market.. PHI exposure is rated High and AI training risk is Medium. AI-assisted interpretation of 2D dental radiographs and visual patient education to improve treatment plan acceptance.
36
Privacy
37
Governance
35
Healthcare
55
AI Risk
Recommended For
Craniocatch
Educational and research purposes; clinical use is currently restricted in the United States due to the absence of FDA marketing authorization.
Currently under review — not recommended for active PHI deployment
Allisone
AI-assisted interpretation of 2D dental radiographs and visual patient education to improve treatment plan acceptance.
Currently under review — not recommended for active PHI deployment
Governance Considerations
Craniocatch
PHI exposure is elevated. Review data flow documentation.
Quarterly reviews are required — establish internal review cadence.
Restrictions noted: Lacks verified FDA 510(k) clearance for clinical deployment within the United States as of recent regulatory reviews.
Allisone
PHI exposure is elevated. Review data flow documentation.
Quarterly reviews are required — establish internal review cadence.
Restrictions noted: Intended for use by qualified dental surgeons only; AI findings must be verified by a practitioner. US-based practices must verify HIPAA compliance and BAA availability before use.
Questions to Ask Before Approval
Has the vendor executed a Business Associate Agreement (BAA) with your organization?
Does the vendor use customer data to train AI models? Can you opt out?
Where is PHI stored, processed, and transmitted?
What data retention and deletion policies apply to your PHI?
Has the vendor undergone a third-party HIPAA or SOC 2 audit?
What is the vendor's incident response and breach notification process?
Does the vendor offer audit logging for PHI access?
What subprocessors have access to PHI through this vendor?
Request Vendor Evaluation
Get a structured risk assessment for any vendor.
Request Benchmark Report
Compare vendors across your full stack.
Book Governance Assessment
Talk to a VNDRIQ governance specialist.